STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

Data ReadoutnegativeNegative

AI Analysis

Summary

AstraZeneca and Ionis announced a surprise failure of their heart disease drug candidate. The news is being closely monitored by Alnylam and other competitors in the cardiovascular space.

Outcome Details

AstraZeneca and Ionis heart disease drug failed

Importance:7/10

Sentiment:

-0.80

clinical failureheart diseasepartnershipdrug development

Related Companies

$AZN $IONS $ALNY

Read the original article

Published by STAT News on August 28, 2026 1:39 PM

Read Original